Toll-like receptors in the pathogenesis of chemotherapy-induced gastrointestinal toxicity

Current Opinion in Supportive and Palliative Care

Volumn 10, Issue 2, 2016, Pages 157-164

  Cario, Elke ^a,b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

antimicrobial therapy; bacteria; carcinogenesis; chemotherapy; host defense; intestinal inflammation; mucosal barrier; pattern recognition; Toll like receptor; xenobiotics

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; MULTIDRUG RESISTANCE PROTEIN 1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; XENOBIOTIC AGENT;

ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; DYSBIOSIS; ENVIRONMENT; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE FLORA; INTESTINE MUCOSA; METABOLISM; MUCOSA INFLAMMATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE, SUB-FAMILY B, MEMBER 1; DYSBIOSIS; ENVIRONMENT; GASTROINTESTINAL MICROBIOME; HUMANS; IMMUNITY, INNATE; INTESTINAL MUCOSA; MUCOSITIS; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; XENOBIOTICS;

EID: 84966356221     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000202     Document Type: Review

References (71)

1. McGuire DB, Altomonte V, Peterson DE, et al. Patterns of mucositis and pain in patients receiving preparative chemotherapy and bone marrow transplantation. Oncol Nurs Forum 1993; 20: 1493-1502
2. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98: 1531-1539
3. Murphy BA. Clinical and economic consequences of mucositis induced by chemotherapy and/or radiation therapy. J Support Oncol 2007; 5: 13-21
4. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120: 1453-1461
5. Villa A, Sonis ST. Mucositis: pathobiology and management. Curr Opin Oncol 2015; 27: 159-164
6. Aparicio-Domingo P, Romera-Hernandez M, Karrich JJ, et al. Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage. J Exp Med 2015; 212: 1783-1791
7. Kamada N, Nunez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 2014; 146: 1477-1488
8. Ramos MG, Bambirra EA, Cara DC, et al. Oral administration of shortchain fatty acids reduces the intestinal mucositis caused by treatment with Ara-C in mice fed commercial or elemental diets. Nutr Cancer 1997; 28: 212-217
9. Klaassen CD, Cui JY. Review: Mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos 2015; 43: 1505-1521
10. Carmody RN, Turnbaugh PJ. Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics. J Clin Invest 2014; 124: 4173-4181
11. Stringer AM, Gibson RJ, Logan RM, et al. Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracilinduced gastrointestinal mucositis. Exp Biol Med (Maywood) 2009; 234: 430-441
12. Fijlstra M, Ferdous M, Koning AM, et al. Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model. Support Care Cancer 2015; 23: 1513-1522
13. Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy-or radiation-induced gastrointestinal mucositis-current evidence and potential clinical applications. Aliment Pharmacol Ther 2014; 40: 409-421
14. Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nat Immunol 2015; 16: 343-353
15. Cario E. Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr Opin Gastroenterol 2013; 29: 85-91
16. Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res 2012; 72: 3948-3957
17. Ey B, Eyking A, Gerken G, et al. TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injury. J Biol Chem 2009; 284: 22332-22343
18. Ey B, Eyking A, Klepak M, et al. Loss of TLR2 worsens spontaneous colitis in MDR1A deficiency through commensally induced pyroptosis. J Immunol 2013; 190: 5676-5688
19. Ciorba MA, Riehl TE, Rao MS, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 2012; 61: 829-838
20. Jones RM, Desai C, Darby TM, et al. Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway. Cell Rep 2015; 12: 1217-1225
21. Borst P, Schinkel AH. P-glycoprotein ABCB1: a major player in drug handling by mammals. J Clin Invest 2013; 123: 4131-4133
22. Mercado-Lubo R, McCormick BA. The interaction of gut microbes with host ABC transporters. Gut Microbes 2010; 1: 301-306
23. Frank M, Hennenberg EM, Eyking A, et al. TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 2015; 194: 1983-1995
24. Shah P, Guo T, Moore DD, Ghose R. Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drugmetabolizing enzymes and transporters. Drug Metab Dispos 2014; 42: 172-181
25. Wang S, Lei T, Zhang K, et al. Xenobiotic pregnane X receptor (PXR) regulates innate immunity via activation of NLRP3 inflammasome in vascular endothelial cells. J Biol Chem 2014; 289: 30075-30081
26. Kim J. Poly(ADP-ribose) polymerase activation induces high mobility group box 1 release from proximal tubular cells during cisplatin nephrotoxicity. Physiol Res 2015; 8: 8
27. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284
28. Crews KR, Zhou Y, Pauley JL, et al. Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia. Cancer 2010; 116: 227-232
29. Cario E. Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis 2010; 16: 1583-1597
30. de Koning BA, van Dieren JM, Lindenbergh-Kortleve DJ, et al. Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol 2006; 18: 941-949
31. Hamada K, Kakigawa N, Sekine S, et al. Disruption of ZO-1/claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis. Cancer Chemother Pharmacol 2013; 72: 757-765
32. Bosisio D, Polentarutti N, Sironi M, et al. Stimulation of Toll-like receptor 4 expression in human mononuclear phagocytes by interferon-gamma: a molecular basis for priming and synergism with bacterial lipopolysaccharide. Blood 2002; 99: 3427-3431
33. Venkatesh M, Mukherjee S, Wang H, et al. Symbiotic bacterial metabolites regulate gastrointestinal barrier function via the xenobiotic sensor PXR and Toll-like receptor 4. Immunity 2014; 41: 296-310
34. Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol 2015; 21: 12234-12248
35. Polumuri SK, Jayakar GG, Shirey KA, et al. Transcriptional regulation of murine IL-33 by TLR and non-TLR agonists. J Immunol 2012; 189: 50-60
36. Guabiraba R, Besnard AG, Menezes GB, et al. IL-33 targeting attenuates intestinal mucositis and enhances effective tumor chemotherapy in mice. Mucosal Immunol 2014; 7: 1079-1093
37. Gibson RJ, Coller JK, Wardill HR, et al. Chemotherapy-induced gut toxicity and pain: involvement of TLRs. Support Care Cancer 2015. [Epub ahead of print
38. Ungaro R, Fukata M, Hsu D, et al. A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1167-1179
39. Wong DV, Lima-Junior RC, Carvalho CB, et al. The adaptor protein Myd88 is a key signaling molecule in the pathogenesis of irinotecan-induced intestinal mucositis. PLoS One 2015; 10: e0139985
40. Wardill HR, Van Sebille YZ, Mander KA, et al. Toll-like receptor 4 signaling: a common biological mechanism of regimen-related toxicities: an emerging hypothesis for neuropathy and gastrointestinal toxicity. Cancer Treat Rev 2015; 41: 122-128
41. Agalave NM, Larsson M, Abdelmoaty S, et al. Spinal HMGB1 induces TLR4-mediated long-lasting hypersensitivity and glial activation and regulates painlike behavior in experimental arthritis. Pain 2014; 155: 1802-1813
42. Calil IL, Zarpelon AC, Guerrero AT, et al. Lipopolysaccharide induces inflammatory hyperalgesia triggering a TLR4/MyD88-dependent cytokine cascade in the mice paw. PLoS One 2014; 9: e90013
43. Kawasaki K, Akashi S, Shimazu R, et al. Mouse Toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J Biol Chem 2000; 275: 2251-2254
44. Li Y, Adamek P, Zhang H, et al. The cancer chemotherapeutic paclitaxel increases human and rodent sensory neuron responses to TRPV1 by activation of TLR4. J Neurosci 2015; 35: 13487-13500
45. Niu QY, Li ZY, Du GH, Qin XM. H NMR based metabolomic profiling revealed doxorubicin-induced systematic alterations in a rat model. J Pharm Biomed Anal 2015; 118: 338-348
46. Westman Erin L, Canova Marc J, Radhi Inas J, et al. Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol 2012; 19: 1255-1264
47. Napeñas JJ, Brennan MT, Coleman S, et al. Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study.Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 2010; 109: 554-560
48. La Scola B, Raoult D. Molecular identification of Gemella species from three patients with endocarditis. J Clin Microbiol 1998; 36: 866-871
49. Han XY, Kamana M, Rolston KVI. Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases. J Clin Microbiol 2006; 44: 160-165
50. Koppe U, Suttorp N, Opitz B. Recognition of Streptococcus pneumoniae by the innate immune system. Cell Microbiol 2012; 14: 460-466
51. Nozaki N, Shishido T, Takeishi Y, Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in Toll-like receptor-2-knockout mice. Circulation 2004; 110: 2869-2874
52. Kaczmarek A, Brinkman BM, Heyndrickx L, et al. Severity of doxorubicininduced small intestinal mucositis is regulated by the TLR-2 and TLR-9 pathways. J Pathol 2012; 226: 598-608
53. Nigro G, Rossi R, Commere PH, et al. The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. Cell Host Microbe 2014; 15: 792-798
54. Schnetzke U, Spies-Weisshart B, Yomade O, et al. Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia. Genes Immun 2015; 16: 83-88
55. Coller JK, White IA, Logan RM, et al. Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study. Support Care Cancer 2015; 23: 1233-1236
56. Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 deficiency. Gastroenterology 2009; 137: 209-220
57. Eyking A, Ey B, Runzi M, et al. Toll-like receptor 4 variant D299G induces features of neoplastic progression in Caco-2 intestinal cells and is associated with advanced human colon cancer. Gastroenterology 2011; 141: 2154-2165
58. Vuononvirta J, Peltola V, Mertsola J, He Q. Risk of repeated Moraxella catarrhalis colonization is increased in children with Toll-like receptor 4 Asp299Gly polymorphism. Pediatr Infect Dis J 2013; 32: 1185-1188
59. Nachtigall I, Tamarkin A, Tafelski S, et al. Polymorphisms of the Toll-like receptor 2 and 4 genes are associated with faster progression and a more severe course of sepsis in critically ill patients. J Int Med Res 2014; 42: 93-110
60. Hartford CM, Dolan ME. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 2007; 8: 1159-1168
61. Yomade O, Spies-Weisshart B, Glaser A, et al. Impact of NOD2 polymorphisms on infectious complications following chemotherapy in patients with acute myeloid leukaemia. Ann Hematol 2013; 92: 1071-1077
62. Montassier E, Gastinne T, Vangay P, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 2015; 42: 515-528
63. Wallace BD, Wang H, Lane KT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science 2010; 330: 831-835
64. Brandi G, Dabard J, Raibaud P, et al. Intestinal microflora and digestive toxicity of irinotecan in mice. Clin Cancer Res 2006; 12: 1299-1307
65. Alimonti A, Satta F, Pavese I, et al. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann Oncol 2003; 14: 805-806
66. Morgun A, Dzutsev A, Dong X, et al. Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut 2015; 64: 1732-1743
67. Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013; 342: 967-970
68. Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 2013; 342: 971-976
69. Paulos CM, Wrzesinski C, Kaiser A, et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest 2007; 117: 2197-2204
70. Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084-1089
71. Vetizou M, Pitt JM, Daillere R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 2015; 350: 1079-1084